

Brilliant Violet 421™ anti-human IFN-γ

Catalog # / Size: 3112660 / 100 tests
3112655 / 25 tests

Clone: 4S.B3

Isotype: Mouse IgG1, κ


Immunogen: Partially purified, native human IFN-γ

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific




Human peripheral blood lymphocytes were stimulated with PMA + Ionomycin for 6 hours (in the presence of monensin), surface stained with CD3 FITC, fixed, permeabilized, and then stained with IFN-γ (clone 4S.B3) Brilliant Violet 421™ (top) or mo

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by

U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: **ELISA or ELISPOT Detection⁵:** The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody.

Flow Cytometry^{3,4,6-8}: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN- γ - producing cells within mixed cell populations.

Additional reported applications (for the relevant formats) include:

neutralization^{1,2}, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN- γ .

Note: For testing human IFN- γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.

- Application References:**
1. Meager A, *et al.* 1984. *J. Interferon Res.* 4:619. (Neut)
 2. Meager A, 1987. *Lymphokines and Interferons: A Practical Approach.* IRL Press Ltd, Oxford, p. 105. (Neut)
 3. Sester M, *et al.* 2002. *J. Virol.* 76:3748. (ICFC)
 4. Infante-Duarte C, *et al.* 2000 *J. Immunol.* 165:6107. (ICFC)
 5. Goodier M, *et al.* 2000. *J. Immunol.* 165:139. (ELISA)
 6. Chen H, *et al.* 2005. *J. Immunol.* 175:591. (ICFC)
 7. Smeltz RB, 2007. *J. Immunol.* 178:4786. (ICFC)
 8. Iwamoto S, *et al.* 2007. *J. Immunol.* 179:1449. (ICFC) [PubMed](#)
 9. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (ICFC)

Description: Interferon- γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN- γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN- γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

- Antigen References:**
1. Fitzgerald K, *et al.* Eds. 2001. *The Cytokine FactsBook.* Academic Press, San Diego.
 2. De Maeyer E, *et al.* 1992. *Curr. Opin. Immunol.* 4:321.
 3. Farrar M, *et al.* 1993. *Annu. Rev. Immunol.* 11:571